Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce a major milestone for the company’s dermatology pipeline: the commencement of patient recruitment for its SKNJCT-004 Phase 2 clinical study, designed to non-invasively treat basal cell carcinoma of the skin. The trial has officially begun enrolling participants at the Cleveland Clinic Abu Dhabi, following earlier “study may proceed” approval granted by the UAE Department of Health. Bokhari explained that the study is expected to randomize 36 patients across four leading medical centers in the UAE. In addition to Cleveland Clinic Abu Dhabi, recruitment is set to begin at several other prominent institutions, including Sheikh Shakbout Medical City, Burjeel Medical City, Rashid Hospital, Clemenceau Medical Center, and the American Hospital of Dubai. This multi-center approach aims to accelerate enrollment while ensuring the study draws on a broad and diverse patient population. The SKNJCT-004 trial will assess the efficacy of two dose levels of Medicus Pharma’s investigational therapy D-MNA compared to a placebo control. Participants will be randomized in a 1:1:1 ratio into three groups: a placebo group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA. The company believes that a non-invasive therapy could transform the standard of care for BCC by offering patients an alternative to surgery or other destructive modalities. Bokhari also highlighted that Medicus Pharma continues to advance its broader clinical program targeting BCC. The company’s SKNJCT-003 Phase 2 study is currently underway at nine clinical sites across the United States, with patient randomization having commenced in August 2024. In March 2025, the company reported a positively trending interim analysis from SKNJCT-003, demonstrating more than 60% clinical clearance—an encouraging early indicator of the therapy’s potential efficacy. The company has also closed its acquisition of Antev, a UK-based biotech focused on next-generation gonadotrophin releasing hormone antagonists, noting the company now controls three FDA-approved clinical studies. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation